• Cardinal Health recently declared a quarterly dividend of US$0.5158 per share, payable on July 15, 2026, to shareholders of record on July 1, 2026, while also lifting its full-year fiscal 2026 non-GAAP EPS outlook and lowering its expected effective tax rate following mixed-to-positive third-quarter results.
• The company’s Pharmaceutical & Specialty Solutions segment has been a key earnings engine, with strong specialty drug demand and expanding partnerships in areas such as oncology and urology helping to offset recent share price volatility and concerns about valuation.
• With Cardinal Health raising its fiscal 2026 earnings guidance, we’ll now examine how this stronger outlook reshapes the company’s broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to be comfortable with a volume-driven distribution model that runs on thin margins but benefits from scale, especially in specialty pharmaceuticals. The latest dividend increase and upgraded fiscal 2026 EPS guidance support the near term earnings catalyst, while the most immediate risk still looks tied to valuation concerns and potential pressure if regulatory or reimbursement conditions tighten. Overall, this news does not materially change the core risk profile.

The most relevant update here is management’s decision to raise full year fiscal 2026 non GAAP EPS guidance while lowering its expected effective tax rate. That combination reinforces earnings momentum as a key short term driver, particularly with the Pharmaceutical & Specialty Solutions segment already posting strong specialty volume growth, yet it also sharpens the focus on whether higher profitability can offset concerns about pricing scrutiny and compressed distribution margins over time.

Yet despite the raised outlook and dividend increase, investors should be aware of...

Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see Cardinal Health’s fair value between US$245 and about US$466, highlighting very different expectations for upside. When you set those views against the risk that tighter government regulation and pricing scrutiny could pressure already thin distribution margins, it becomes clear why you may want to explore several alternative viewpoints before deciding how this stock fits into your portfolio.

Explore 3 other fair value estimates on Cardinal Health - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.